Background: Intravenous continuous rate infusion (IVCRI) of lispro at a starting dose
DKA in cats include the use of IV continuous rate infusion (IVCRI) regular insulin, intermittent IM injection of regular insulin, a combination of IM regular insulin and SC glargine, or a combination of IM and SC glargine. [1] [2] [3] [4] The use of IVCRI lispro insulin for treatment of DKA in cats has also been described in a case series in which cats were treated with an initial insulin dose 0.045 U/kg/h. 5 It is important to validate alternative IVCRI insulin treatment protocols because the production of regular insulin could be discontinued. According to the 2017 annual report of Eli Lilly, the revenue associated with lispro is now more than double the revenue associated with regular insulin (https://investor.lilly.com/financialinformation/annual-reports). Additionally, the patent for lispro has expired in several countries, and a Sanofi-Aventis lispro insulin has been granted FDA approval in the United States and European Medicines Agency approval in the European Union (https://www.fda.gov/newsevents/ newsroom/pressannouncements/ucm588466.htm; http://www.ema.
europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 004303/human_med_002129.jsp&mid=WC0b01ac058001d124). These factors could contribute to a more competitive pricing of lispro and could influence its use in veterinary medicine.
Lispro is a genetically engineered human analogue insulin in which proline at position B28 and lysine at position B29 are transposed. 6 In humans with critical illness, IVCRI of lispro more rapidly decreases blood glucose (BG) concentration, and with lower risk of hypoglycemia, compared to IVCRI of regular insulin. 7 In dogs, the median time to resolution of hyperglycemia, ketosis, and acidosis with IVCRI of lispro is significantly shorter (26 hours; range 26-50 hours) than in dogs treated with IVCRI of regular insulin (61 hours; range, 38-80 hours; P = .02) when the initial insulin dose of both products is 0.09 U/kg/h. 8 In cats, the median times to resolution of hyperglycemia, ketosis, or acidosis with IVCRI of lispro are not significantly different (8, 29 , or 8 hours, respectively) than these times when cats are treated with IVCRI of regular insulin (9, 26.5, or 20 hours, respectively) when the initial insulin dose of both products is 0.045 U/kg/h. 5 The median times to resolution of hyperglycemia, ketosis, or acidosis in cats with intermittent IM regular insulin administered in combination with SC glargine insulin are significantly shorter (9, 44, or 23 hours, respectively) than times in cats treated with IVCRI of regular insulin (12, 62 , or 41 hours, respectively) when the initial insulin dose of the IVCRI is 0.045 U/kg/h. 3 For the purpose of the current study, an initial IVCRI insulin dose of 0.09 U/kg/h (prepared by adding 2.2 U/kg/240 mL bag of 0.9% NaCl) was chosen rather than an initial IVCRI insulin dose of 0.045 U/kg/h because treatment with the higher dose has been associated with a better prognosis in cats with DKA. 1 The type of fluid used for resuscitation has not been standardized in cats with DKA. Although 0.9% NaCl is recommended for the initial phase of fluid resuscitation and as long as hyponatremia is present in humans with DKA, the use of 0.9% NaCl has not been investigated in an original study of cats with DKA. 9 Similarly, protocols for correction of potassium, phosphate, and magnesium deficiencies in cats with DKA have not been established.
The objectives of this study were 3-fold. The first objective was to further characterize the use of IVCRI lispro for the treatment of DKA in cats in a randomized, controlled, blinded study in which cats received an initial IVCRI of lispro or regular insulin at a dose of 0.09 U/kg/h, and to compare the times to resolution of hyperglycemia, ketosis, and acidosis in cats treated with lispro and regular insulin IVCRI at this dose. The second objective was to characterize the use of 0.9% NaCl for fluid resuscitation and determine if this treatment is effective and safe in resolving hyponatremia in cats with DKA. The third objective was to explore new protocols for electrolyte supplementation in cats with DKA while using solutions with higher than previously reported electrolyte concentrations to correct low serum concentrations of potassium, phosphate, and magnesium. This study had 3 hypotheses. The first was that lispro insulin is effective and safe in treating DKA in cats and that resolution of hyperglycemia would be faster in cats treated with lispro insulin compared to those treated with the same dose of regular insulin. The second hypothesis was that 0.9% NaCl is effective and safe for treatment of hyponatremia in cats with DKA. The third hypothesis was that electrolyte supplementation with solutions that contain higher than previously reported electrolyte concentrations are effective and safe in correction of low serum concentrations of potassium, phosphate, and magnesium in cats with DKA.
| MATERIALS AND METHODS

| Study design
A prospective, randomized, controlled, blinded clinical study was performed. Client-owned cats with naturally occurring DKA were randomly assigned to receive either lispro or regular insulin IVCRI. Twelve sealed opaque envelopes containing either 1 of 6 "Lispro insulin" or 1 of 6 "Regular insulin" inserts were used, and the insulin assignment was known to nurses only, until the cat was discharged from the hospital or euthanized. Cats examined at a veterinary university hospital were enrolled between July 2011 and July 2013. Inclusion criteria were clinical signs suggestive of DM (polyuria, polydipsia, polyphagia, or weight loss), BG >300 mg/dL, serum Bhydroxybutyrate (BOHB) >2 mmol/L, venous pH <7.35, glucosuria on urine dipstick, and a signed owner consent form (which included consent for necropsy should the cat die or be euthanized during hospitalization).
The study protocol and owner consent form were approved by the University's Institutional Animal Care and Use Committee. Cats were excluded if venous pH was <7.0 or if the owner did not consent. The study protocol called for exclusion of cats with a venous pH <7.0 because in dogs and humans with DKA, this pH is associated with death. 9, 10 Ultimately, none of the cats were excluded from the study due to pH <7.0.
| Treatment protocol
Upon admission, all cats received IV fluid resuscitation with 0.9% NaCl. The initial fluid rate and bolus rate were determined by the emergency clinician based on the cat's body weight, estimated percentage of dehydration, estimated ongoing fluid losses, and maintenance fluid requirements. A fluid bolus was administered over a 20-minute time period if the cardiovascular system evaluation indicated that it was needed. Fluid boluses were not supplemented with electrolytes. The cardiovascular system evaluation included an assessment of the mucous membrane color, capillary refill time, heart rate, pulse quality, and extremities' temperature. The cardiovascular status of each cat was reevaluated every 20-120 minutes depending on the rate of fluid administration and the initial cardiovascular system evaluation to determine the need for fluid rate adjustments.
The study protocol required that IVCRI of insulin begin after 6 hours of fluid resuscitation. However, the emergency room clinician was given discretion to deviate from the protocol as dictated by the clinical needs of each cat. Identical protocols were used for IVCRI of regular and lispro insulin, as described in Table 1 . The initial dose of IVCRI insulin was 0.09 U/kg/h. Serum potassium concentration was corrected as described in 
| Definitions of the time of SC insulin administration and duration of hospitalization
The time to SC insulin administration was defined as the time interval from admission until SC glargine was administered. Glargine was administered once acidosis had resolved and the cat was eating well.
The IVCRI of insulin was discontinued 4-6 hours before the planned administration of SC glargine to ensure that the cat had some degree of hyperglycemia before glargine administration. The duration of hospitalization was defined as the time interval between admission and the time at which the cat was discharged from the hospital or euthanized. 200-300 0.9% NaCl + 2.5% dextrose 7
| Evaluation for the presence of concurrent disorders
150-199 0.9% NaCl + 2.5% dextrose 5 100-149 0.9% NaCl + 5% dextrose 5 <100 0.9% NaCl + 5% dextrose Stop insulin infusion *2.2 U/kg of regular or lispro insulin (Humulin R or Humalog; Eli Lilly and Co, Indianapolis, Indiana) were added to a 250 mL bag of 0.9% NaCl. 10 mL were discarded from the bag before adding insulin. The bag was labeled by a nurse as containing insulin with no reference to regular or lispro insulin. The fluid line was flushed with 50 mL of insulin solution before starting the IV continuous rate infusion.
T A B L E 2 Protocol for IV continuous rate infusion of potassium supplementation in cats with diabetic ketoacidosis as a heart rate <160 bpm, and hypothermia was defined as a temperature <99.5 F.
| Monitoring
Blood glucose concentration was measured every 2 hours, and all reported values were measured with a point-of-care glucometer during the entire time that the cat received an IVCRI of insulin (AccuCheck Aviva; Roche Diagnostics Corp, Indianapolis, Indiana). 15 Serum sodium, potassium, and pH were measured from anaerobically handled and processed venous blood gas samples every 4-8 hours, and all reported values were measured with a point-of-care analyzer (Stat Profile; NOVA Biomedical Corporation). For each cat, the difference between the corrected sodium concentration at admission and the lowest corrected sodium concentration reached throughout the study was divided by the number of hours from admission to the time at which the lowest corrected sodium concentration was measured. Similarly, for each cat, the difference between the corrected sodium concentration at admission and the highest corrected sodium concentration reached throughout the study was divided by the number of hours from admission to the time at which the highest corrected sodium concentration was measured. These calculations were performed to determine the 
| RESULTS
Twelve cats were enrolled in the study. Six cats were randomized into the lispro insulin treatment group (LITG) and the other 6 cats were randomized into the regular insulin treatment group (RITG). Eighteen cats with confirmed DKA were excluded from the study during the study period. Ten of these 18 cats were euthanized at the time of admission at the request of their owners. Four cats were admitted for treatment but their owners refused to enroll the cat in the study, and 2 other cats were taken elsewhere for treatment. One cat was not enrolled because the hospital staff forgot to offer enrollment, and another cat was not enrolled because all the researchers were away at the time. Four additional cats with DM and suspected DKA were excluded because they did not meet all of the inclusion criteria. Three of these 4 cats had a BG <300 mg/dL and 1 cat had BOHB <2 mmol/L. Eight of the 12 study cats were discharged from the hospital and 4 (2 from each insulin treatment group) were euthanized. Data pertain to all 12 cats, except when specifically noted.
| Signalment, history, clinical signs, and physical examination findings
The median age of enrolled cats was 8 years (range 0.6-13 years).
Eleven cats were domestic short-haired cats and 1 was a Maine Coon cat. Six cats were neutered males, 5 were neutered females, and 1 cat was an intact female. The median weight at discharge was 4.83 kg (range 2.48-6.37 kg).
Seven cats had newly diagnosed DM at the time of enrollment were not given to any of the cats at the time of admission nor were they reported to have been given in the past.
At the time of admission, the most common physical examination abnormalities included dehydration (noted in 11 cats), lethargic mental status (8 cats), muscle wasting (7 cats), bradycardia (7 cats), and hypothermia (5 cats).
| Concurrent disorders
One cat, from the RITG, was euthanized within the first 24 hours of hospitalization and did not have imaging studies performed. Eleven of 12 cats had thoracic radiographs, which revealed hepatomegaly (in 10 cats), bronchial pattern (6 cats), cardiomegaly (4 cats), pleural effusion (1 cat), and bronchiectasis (1 cat). Abdominal ultrasound was performed in 11 of 12 cats and revealed hyperechoic small intestinal thickening (in 6 cats), hepatomegaly (5 cats), renomegaly (4 cats), and lymphadenopathy (3 cats).
Two cats, both from the RITG, were diagnosed with acute pancreatitis.
There was no aerobic growth on the bacterial culture of urine collected via cystocentesis in any of the 12 cats. One cat was FIV positive, while the rest were FeLV and FIV negative. All cats had a thyroid hormone concentration <1 μg/dL. Abnormalities noted on CBC, biochemistry profiles, and urinalyses were similar to those previously reported in cats with DKA. 1 Four cats (2 from each insulin treatment group) were euthanized during hospitalization and were not discharged from the hospital.
Antemortem, all 4 cats had hypotension, 1 had pulmonary edema, and another was obtunded. They were euthanized at a median of 54 hours after admission (range 13-94 hours). All 4 cats had evidence of moderate to severe hepatic lipidosis on necropsy. Other necropsy findings included enteritis (3), pulmonary edema (2), adrenal necrosis and hemorrhage (2), necrotizing pancreatitis (1), and chronic tubular interstitial nephritis (1).
| Initial fluid treatment and initiation of IVCRI insulin
Initial fluid treatment consisted of a 20-minute fluid bolus in 11 of 12 cats. Six of these cats were in the LITG and 5 were in the RITG. The median fluid bolus rate given to cats in the LITG and RITG was 15 mL/kg/h (10-20 mL/kg/h) and 20 mL/kg/h (20-30 mL/kg/h), respectively. One cat in the RITG did not require a fluid bolus and received an initial fluid rate of 4 mL/kg/h. After the bolus, the median fluid rate given to 6 cats in the LITG and 5 cats in RITG was 5 mL/kg/h (4-7 mL/kg/h) and 4 mL/kg/h (4-6 mL/kg/h), respectively. Two cats (1 from each treatment group) received dopamine at 5-10 μg/kg/min or 12.5-15 μg/kg/min. These 2 cats were among the 4 cats that were euthanized.
The median time interval between admission time (when fluid resuscitation was initiated) until IVCRI of insulin began was 7.5 hours for the LITG (range 4-14 hours) and 7 hours for the RITG (range 6-9 hours). The median BG in all 12 cats at the time that IVCRI of insulin began was 344 mg/dL (175-579 mg/dL) and was significantly lower than the median BG at the time that fluid resuscitation was initiated (491 mg/dL, 300-698 mg/dL; P = .008). 
| Adverse drug reactions
| Resolution of hyperglycemia, ketosis, and acidosis
Median BG concentration, BOHB concentration, and pH at the time of admission to the hospital and during the first 96 hours of hospitalization are reported in Table 3 . Some of the reporting related to BG, ketosis, and acidosis is limited to the first 96 hours of hospitalization because most of these variables normalized within this time frame.
The median times to resolution of hyperglycemia, ketosis, and acidosis are also reported in Table 3 . 
| Time of SC insulin administration and duration and cost of hospitalization
| Electrolyte concentrations
Electrolyte concentrations are reported in Table 4 
| DISCUSSION
The median time to resolution of initial pronounced hyperglycemia was significantly shorter in the LITG compared with the RITG. However, when focusing on the lowest BG measured in each of the cats throughout the study, it was noted that the median lowest BG in the LITG was significantly higher than the median lowest BG in the RITG.
It was therefore concluded that in cats with DKA, lispro insulin leads to a faster resolution of initial pronounced hyperglycemia, with less overall risk of hypoglycemia compared to regular insulin. However, larger studies including more cats with hypoglycemia are needed to further investigate these findings and potential conclusion.
Faster resolution of initial pronounced hyperglycemia with less overall risk of hypoglycemia has also been documented in humans with critical illness and is attributed to the rapid onset of action and shorter duration of action of lispro when compared to regular insulin. insulin are combined to decrease BG. 8 This concern over early IVCRI of insulin administration is different than the conclusion reached in a retrospective study which concluded that early insulin treatment (within the first 6 hours of hospital admission) resulted in faster resolution of ketonuria compared to when insulin was given after 6 hours of admission. 13 However, because of the retrospective nature of the study, it is not known why some patients received insulin later than others. It is possible that patients with severe morbidity received insulin later than others, and due to this severe morbidity had later resolution of ketonuria, which was unrelated to the time at which the insulin treatment began. 13 It is important to note that the more rapid resolution of hyperglycemia observed in the LITG compared to the RITG is probably not The same fluid type, 0.9% NaCl, was administered for fluid resuscitation, maintenance fluid therapy, and as a vehicle for IVCRI insulin administration in all cats. This is the first such use of 0.9% NaCl reported in an original study of cats with DKA. Original studies of DKA treatment in cats have not reported the type of fluid used for resuscitation or reported more than 1 fluid type for this purpose. [3] [4] [5] 13, 14 One study did report using 0.9% NaCl only for IVCRI insulin administration, similar to the protocol used in this study. 3 The protocol for IVCRI insulin administration reported in most studies is based on a study of dogs with DKA. 15 In the dog study, it was recommended that IVCRI insulin administration begin with 0.9% NaCl and be switched to 0.45% NaCl with dextrose when BG dropped below 250 mg/dL. 15 This recommendation is technically laborious and could have been made due to concerns over hypernatremia. The results of this study support the continued use of 0.9% NaCl for both fluid resuscitation and IVCRI insulin administration. The highest corrected sodium concentration reported after 0.9% NaCl resuscitation began was 159 mmol/L, and this mild hypernatremia was documented in only 2 cats.
The median highest corrected sodium concentrations remained within the reference range. Hyponatremia, on the other hand, was more common and more severe. It developed or was maintained in 9 cats, and the median lowest corrected sodium concentrations recorded throughout the study were below the reference range. Although there were significant differences in the corrected sodium concentration between the LITG and the RITG at the time of initial examination, these differences resolved with 0.9% NaCl treatment. The hourly change in corrected sodium concentration never exceeded 1 mmol/L/h. It is therefore concluded that 0.9% NaCl is a suitable initial fluid choice for both resuscitation and IVCRI insulin administration in cats with DKA. However, randomized controlled clinical trials comparing outcomes of treatment in cats with DKA treated with different fluid types are needed to substantiate the findings reported in this study.
Protocols for potassium supplementation in cats with DKA are either not described or utilize a protocol established for dogs with DKA. [3] [4] [5] [13] [14] [15] However, cats require different electrolyte supplementation protocols with higher electrolyte concentration solutions because the total volume of fluid infused to cats is smaller than that administered to dogs. With this in mind, new protocols for potassium, magnesium, and phosphate supplementation for cats with DKA were used in this study. Despite the higher concentration of potassium solution used for treatment, all cats maintained or developed hypokalemia at some point throughout the study. However, the hypokalemia was mild, indicating that this potassium supplementation protocol is effective.
Despite the higher potassium infusion rates in this study, hyperkalemia was uncommon. Hyperkalemia was documented in only 3 cats 1 of which developed a hyperkalemia of 6.8 mmol/L. However, hyperkalemia can be fatal. Therefore, cats receiving high fluid rates with potassium supplementation should have potassium concentration measured hourly and potassium supplementation recalculated accordingly, to avoid the risk of hyperkalemia.
This study has several limitations. First, it is a small study, which was undertaken to ascertain the safety and effectiveness of a new lispro insulin IVCRI protocol. Another limitation is that cats with DKA have concurrent illness. 1 Therefore, response to treatment and electrolyte concentrations were likely influenced not only by treatment protocols but also by the presence of concurrent diseases. Additionally, the protocol required that IVCRI of insulin begin after 6 hours of fluid resuscitation. However, the emergency room clinician was given latitude to deviate from the protocol and IVCRI of insulin was begun up to 14 hours after fluid resuscitation was initiated. It is not known why some cats had IVCRI insulin introduced later than others. Possible explanations could include the busy and unpredictable setting of an emergency room, ongoing conversations with the owners about the decision to treat or enroll in the trial, and the cardiovascular status of the cat. The effect of these limitations on the study findings is not known.
In conclusion, IVCRI lispro insulin administered at an initial dose of 0.09 U/kg/h is safe and effective for treatment of DKA in cats. Should regular insulin become unavailable, or if lispro insulin becomes more competitively priced, lispro insulin is a reasonable option for IVCRI treatment of cats with DKA. Additionally, 0.9% NaCl is effective and safe for treatment of hyponatremia in cats with DKA. Finally, electrolyte supplementation with solutions that contain higher than previously reported electrolyte concentrations are effective and safe for correction of potassium, phosphate, and magnesium deficiencies in cats with DKA. Larger future studies can build on these findings to further validate or modify the treatment protocols reported here.
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